OverviewSuggest Edit

PTC Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of orally-administered, small molecule therapeutics that focus on post-transcriptional control processes. The Company's lead product, Translarna, is used for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients with age of over five years and older. Its programs include Translarna for nonsense mutation cystic fibrosis, Translarna for mucopolysaccharidosis type I caused by nonsense mutation, Translarna for nonsense mutation aniridia, and Translarna for nonsense mutation Dravet syndrome/CDKL5, Spinal muscular atrophy in collaboration with Spinal Muscular Atrophy Foundation.
TypePublic
Founded1998
HQSouth Plainfield, US
Websiteptcbio.com
Employee Ratings3
Overall CultureA

Latest Updates

Employees (est.) (Dec 2019)754(+48%)
Job Openings77
Revenue (FY, 2019)$307 M(+16%)
Share Price (Nov 2020)$59.5
Cybersecurity ratingCMore

Key People/Management at PTC Therapeutics

Stuart Peltz

Stuart Peltz

CEO
Neil Almstead

Neil Almstead

Executive Vice President, Research, Pharmaceutical Operations & Technology
Mark Boulding

Mark Boulding

Executive Vice President and Chief Legal Officer
Mary Harmon

Mary Harmon

Senior Vice President, Corporate Relations
VMD Mark J. Pykett

VMD Mark J. Pykett

Chief Innovation Officer
Martin Rexroad

Martin Rexroad

Senior Vice President, Human Resources
Show more

PTC Therapeutics Office Locations

PTC Therapeutics has an office in South Plainfield
South Plainfield, US (HQ)
100 Corporate Ct
Show all (1)

PTC Therapeutics Financials and Metrics

PTC Therapeutics Revenue

PTC Therapeutics's revenue was reported to be $306.98 m in FY, 2019
USD

Revenue (Q3, 2020)

118.4m

Net income (Q3, 2020)

(69.7m)

EBIT (Q3, 2020)

(55.1m)

Market capitalization (12-Nov-2020)

4.1b

Closing stock price (12-Nov-2020)

59.5

Cash (30-Sept-2020)

434.0m

EV

4.0b
PTC Therapeutics's current market capitalization is $4.1 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

34.7m25.2m36.8m82.7m194.4m264.7m307.0m

Revenue growth, %

(27%)46%125%

Cost of goods sold

4.6m12.7m12.1m

Gross profit

189.8m252.1m294.8m
Quarterly
USDQ2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

6.9m16.3m9.2m1.7m1.7m7.5m6.8m9.8m18.9m15.6m23.0m26.5m48.0m41.9m56.1m68.7m53.6m53.6m85.5m71.4m68.3m75.2m118.4m

Cost of goods sold

39.0k758.0k1.6m3.0m2.6m3.3m2.4m3.2m3.0m

Gross profit

26.5m47.2m40.3m53.0m66.2m50.3m51.2m82.3m68.4m

Gross profit Margin, %

100%98%96%95%96%94%96%96%96%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

15.4m49.7m58.0m58.3m111.8m169.5m288.0m

Accounts Receivable

4.4m11.1m24.9m40.4m67.9m55.5m

Prepaid Expenses

1.6m3.9m5.9m6.7m9.2m17.9m

Inventories

4.7m10.8m16.1m19.3m
USDQ2, 2013

Financial Leverage

1.1 x
Show all financial metrics

PTC Therapeutics Acquisitions / Subsidiaries

Company NameDateDeal Size
Agilis BiotherapeuticsJuly 20, 2018$200 m

PTC Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

C

74/100

SecurityScorecard logo

PTC Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

PTC Therapeutics Online and Social Media Presence

Embed Graph

PTC Therapeutics Company Culture

  • Overall Culture

    A

    87/100

  • CEO Rating

    B

    75/100

  • Compensation

    A+

    100/100

Learn more on Comparably

PTC Therapeutics News and Updates

PTC Therapeutics Announces Initiation of a Registration-Directed Clinical Trial to Evaluate Vatiquinone in Mitochondrial Epilepsy

SOUTH PLAINFIELD, N.J., Oct. 26, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced the initiation of a registration-directed Phase 2/3 clinical trial to evaluate vatiquinone (PTC743) in patients with mitochondrial epilepsy, the highly morbid condition of...

RareMed Solutions Announces that it has been Selected as the Non-Commercial Dispensing Pharmacy for EMFLAZA® by PTC Therapeutics, Inc.

PITTSBURGH, Oct. 21, 2020 /PRNewswire/ -- RareMed Solutions announces that it has been selected by PTC Therapeutics, Inc. to provide non-commercial dispensing services for the drug EMFLAZA® (deflazacort). RareMed will be the exclusive free drug provider for EMFLAZA®, managing the EMFLAZA®...

PTC Therapeutics Announces Agreement to Monetize a Portion of the Risdiplam Royalty Stream for $650 Million

SOUTH PLAINFIELD, N.J., July 20, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced an agreement to monetize a portion of the risdiplam royalty stream for $650 million from Royalty Pharma plc. The capital from the collaboration will enable PTC to further develop...

PTC Therapeutics Announces the Initiation of a Phase 2/3 Clinical Trial to Evaluate PTC299 for the Treatment of COVID-19

SOUTH PLAINFIELD, N.J., June 17, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced that the U.S. Food and Drug Administration has authorized the initiation of a Phase 2/3 trial to investigate PTC299, a dihydroorotate dehydrogenase (DHODH) inhibitor, as a...

PTC Therapeutics Announces FDA Grants Priority Review to Risdiplam for the Treatment of Spinal Muscular Atrophy

SOUTH PLAINFIELD, N.J., Nov. 25, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the United States Food and Drug Administration (FDA) has granted priority review for the New Drug Application (NDA) for risdiplam (RG7916) for the treatment of spinal muscular...

PTC Therapeutics Announces Proposed Private Offering of Convertible Senior Notes

SOUTH PLAINFIELD, N.J., Sept. 17, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today that it is commencing an offering of $250.0 million aggregate principal amount of its convertible senior notes due 2026 (the "Notes"), subject to market conditions and other...
Show more

PTC Therapeutics Blogs

PTC Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Conference

PTC Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Conference Content Import Thu, 11/19/2020 - 08:01 PTC Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Conference Nov 19, 2020 This release is a backfill from a News Wire …

PTC Therapeutics Announces Key Regulatory Designations for PTC596 to Advance Treatment of Two Rare Oncology Indications

PTC Therapeutics Announces Key Regulatory Designations for PTC596 to Advance Treatment of Two Rare Oncology Indications Content Import Wed, 11/18/2020 - 08:02 PTC Therapeutics Announces Key Regulatory Designations for PTC596 to Advance Treatment of Two Rare Oncology Indications …

PTC Therapeutics Announces that PTC518 Has Entered into a Phase 1 Clinical Trial for the Huntington's Disease Program

PTC Therapeutics Announces that PTC518 Has Entered into a Phase 1 Clinical Trial for the Huntington's Disease Program Content Import Tue, 11/17/2020 - 08:03 PTC Therapeutics Announces that PTC518 Has Entered into a Phase 1 Clinical Trial for the Huntington's Disease Program …

PTC Therapeutics Highlights Data on High Disease Burden and Value of Treatment Across Two Rare Diseases

- AADC deficiency associated with high and accumulating disease burden, demonstrating the need for access to an effective therapy -   - Patient and caregiver quality of life study reveals real-life impact of nonsense mutation Duchenne muscular dystrophy and reinforces value of treatment - SOUTH

PTC Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Corporate Update

- Evrysdi™ makes rapid progress with multiple international approvals and strong U.S. launch -   - Total net revenue of $118.4 million, 66% YoY increase; Total net product revenue of $82.7 million, 16% YoY increase -   - Initiated registration-directed trial with vatiquinone (PTC743) for

PTC Therapeutics to Participate at Upcoming Virtual Investor Conferences

PTC Therapeutics to Participate at Upcoming Virtual Investor Conferences Content Import Wed, 10/28/2020 - 08:02 PTC Therapeutics to Participate at Upcoming Virtual Investor Conferences Oct 28, 2020 This release is a backfill from a News Wire Gen…
Show more

PTC Therapeutics Frequently Asked Questions

  • When was PTC Therapeutics founded?

    PTC Therapeutics was founded in 1998.

  • Who are PTC Therapeutics key executives?

    PTC Therapeutics's key executives are Stuart Peltz, Neil Almstead and Mark Boulding.

  • How many employees does PTC Therapeutics have?

    PTC Therapeutics has 754 employees.

  • What is PTC Therapeutics revenue?

    Latest PTC Therapeutics annual revenue is $307 m.

  • What is PTC Therapeutics revenue per employee?

    Latest PTC Therapeutics revenue per employee is $407.1 k.

  • Who are PTC Therapeutics competitors?

    Competitors of PTC Therapeutics include Radius Health, Marinus Pharmaceuticals and Selecta Biosciences.

  • Where is PTC Therapeutics headquarters?

    PTC Therapeutics headquarters is located at 100 Corporate Ct, South Plainfield.

  • Where are PTC Therapeutics offices?

    PTC Therapeutics has an office in South Plainfield.

  • How many offices does PTC Therapeutics have?

    PTC Therapeutics has 1 office.